| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5622733 | Alzheimer's & Dementia | 2014 | 10 Pages |
Abstract
Changes in Aβ1-42, T-tau, and P-tau181P allow diagnosis of AD in its prodromal stage. Conversely, having all three biomarkers in the normal range rules out AD. Intermediate conditions require further patient follow-up.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
José Luis Molinuevo, Kaj Blennow, Bruno Dubois, Sebastiaan Engelborghs, Piotr Lewczuk, Armand Perret-Liaudet, Charlotte E. Teunissen, Lucilla Parnetti,